Type of information: Private placement
Company: Bluebird Bio (USA - MA)
Amount: $550 million
Funding type: private placement
- • On July 27, 2018, bluebird bio announced the closing of its previously announced underwritten public offering of 3,892,308 shares of its common stock, including 507,692 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $162.50 per share.
- • On July 24, 2018, bluebird bio announced the pricing of an underwritten public offering of 3,384,616 shares of its common stock at a public offering price of $162.50 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase up to an additional 507,692 shares of common stock. All of the shares in the offering are to be sold by bluebird bio.
- bluebird bio anticipates the total gross proceeds from the offering (before deducting underwriters’ discounts and commissions and estimated offering expenses) will be approximately $550 million, excluding any exercise of the underwriters’ option to purchase additional shares.
- • On July 23, 2018, bluebird bio announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by bluebird bio. Goldman Sachs & Co. LLC, BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen are acting as joint book-running managers and Wells Fargo Securities is acting as co-manager of the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Therapeutic area: Rare diseases - Genetic diseases